References in classic literature ?
Illi mors gravis incubat, qui notus nimis omnibus, ignotus moritur sibi.
M2 PHARMA-December 22, 2017-Ra Pharmaceuticals Starts Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalised Myasthenia Gravis Patients
Data from Argenx's (EBR: ARGX) Phase 2 proof-of-concept clinical trial of ARGX-113 (efgartigimod) in myasthenia gravis (MG) patients with confirmed generalised muscle weakness has seen positive top-line results, the company announced on Monday.
This information is inaccurate because, although myasthenia gravis is an exclusion criterion, Wolfe et al.
24 January 2017 - The parent company of US-based business process outsourcing call centre, teleservices firm and Anything-as-a-Service provider Mass Markets has acquired a collection of assets from US-based Gravis Marketing, the company said.
Myasthenia gravis (MG) was first described in the seventeenth century, but as an entity it was recognized only 200 years later when Dr Friedrich Jolly described it and named it as "Myasthenia gravis pseudoparalytica".
Myasthenia gravis (MG) is a disease affecting the acetylcholine receptor in the neuromuscular junction.
The case presented here is about unmasking of myasthenia gravis in a patient who received alfa interferon therapy for her chronic hepatitis C.
Synopsis: For more than a thousand years, the dwarves have hidden away from the world in their ravine city of Arx Gravis.
Canada, April 4, 2016 -- A Canadian report on seven cases of severe myasthenia gravis suggests that autologous hematopoietic stem cell transplantation (using a patient's own stem cells) may result in long-term remission that is symptom and treatment free, according to a new study.
OTTAWA, Ont, Canada, April 18, 2016 -- A Canadian report on seven cases of severe myasthenia gravis suggests that autologous hematopoietic stem cell transplantation (using a patient's own stem cells) may result in long-term remission that is symptom and treatment free, according to a new study.
OTTAWA, Ont, Canada, April 4, 2016 -- A Canadian report on seven cases of severe myasthenia gravis suggests that autologous hematopoietic stem cell transplantation (using a patient's own stem cells) may result in long-term remission that is symptom and treatment free, according to a new study.